GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
The role of glucose-stimulated release of GLP-1 in the development of obesity and type 2 diabetes is unclear. We assessed GLP-1 response to oral glucose in a large study population of lean and obese men and women with normal and impaired glucose regulation. Circulating concentrations of glucose, insulin, and GLP-1 during an oral glucose tolerance test (OGTT) were analyzed in individuals with normal glucose tolerance (NGT) (n = 774), prediabetes (n = 525), or screen-detected type 2 diabetes (n = 163) who attended the Danish ADDITION-PRO study (n = 1,462). Compared with individuals with NGT, women with prediabetes or type 2 diabetes had 25% lower GLP-1 response to an OGTT, and both men and women with prediabetes or type 2 diabetes had 16-21% lower 120-min GLP-1 concentrations independent of age and obesity. Obese and overweight individuals had up to 20% reduced GLP-1 response to oral glucose compared with normal weight individuals independent of glucose tolerance status. Higher GLP-1 responses were associated with better insulin sensitivity and β-cell function, older age, and lesser degree of obesity. Our findings indicate that a reduction in GLP-1 response to oral glucose occurs prior to the development of type 2 diabetes and obesity, which can have consequences for early prevention strategies for diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [133]
In the citing paper
“From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [52]
Citations
Cites
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“In type 2 diabetes, the incretin effect is impaired (2,3), but it remains controversial to what extent the defect is caused by a reduced release of incretin hormones and whether this reduction occurs prior to the development of type 2 diabetes.”
BackgroundAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Gender differences in insulin resistance, body composition, and energy balance
Geer, E. B., & Shen, W. (2009) · Gender Medicine · doi:10.1016/j.genm.2009.02.002 · Cited by 913
Seltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883 · cited 4×
“These findings are in agreement with the glucoregulatory effects of GLP-1 (33,34) and with studies showing that infusion of the GLP-1 receptor antagonist exendin-(9-39) reduced first-phase insulin release and decreased insulin action in healthy individuals and in patients with type 2 diabetes (35,36).”
BackgroundMethodResultInfluentialNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide contribute to glucose-stimulated insulin release and therefore play important roles in maintaining normal glucose regulation (1).”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Validation of the insulin sensitivity index (ISI0,120): comparison with other measures
Gutt, M., Davis, C. L., Spitzer, S. B., Llabre, M. M., Kumar, M., Czarnecki, E. M., Schneiderman, N., Skyler, J. S., & Marks, J. B. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00116-3 · Cited by 474
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“A study in w1,500 Danish subjects suggested that the GLP-1 response to oral glucose is reduced in patients with prediabetes or type-2 diabetes [262].”
BackgroundSelf-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020) · Diabetologia · doi:10.1007/s00125-019-05040-3 · Cited by 923
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Sex differences in type 2 diabetes
Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023) · Diabetologia · doi:10.1007/s00125-023-05891-x · Cited by 624
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans
Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases
Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D. M., Brunetti, F. S., Maggisano, V., Russo, D., Foti, D. P., & Brunetti, A. (2020) · Nutrients · doi:10.3390/nu12041066 · Cited by 272
“From a diabetes prevention perspective, the GLP-1-releasing effects of PUFAs could be particularly important, given that obese patients have lower GLP-1 responses to oral glucose than individuals of normal weight, irrespective of the glycemic status [52,53].”
BackgroundIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
“…for new treatments of AUD (Lyon, 2017), nicotine use disorder (Polosa & Benowitz, 2011) and SUD (Klein, 2016), the gut hormone glucagon-like peptide 1 (GLP-1) has received much attention (Eren-Yazicioglu et al., 2021; Fink-Jensen & Vilsbøll, 2016; Jerlhag, 2020; Reddy et al., 2014; Skibicka, 2013).”
BackgroundThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationFærch, K., Vistisen, D., Pacini, G., Torekov, S. S., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., et al. (2016) · Diabetes · doi:10.2337/db16-0240 · Cited by 217
Self-citationImpact of Gut Microbiota on Host Glycemic Control
Gérard, C., & Vidal, H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00029 · Cited by 209
Roles of the Gut in Glucose Homeostasis
Holst, J. J., Gribble, F., Horowitz, M., & Rayner, C. K. (2016) · Diabetes Care · doi:10.2337/dc16-0351 · Cited by 205
“Inconsistency exists between studies about whether incretin secretion is altered in obesity or type 2 diabetes compared with health, and although decreases in GLP-1 secretion usually can be demonstrated (63), no substantial differences, particularly in the early postprandial phase, have been found (64).”
BackgroundIepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193
Self-citationIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Recent advances in biosensor technology in assessment of early diabetes biomarkers
Salek-Maghsoudi, A., Vakhshiteh, F., Torabi, R., Hassani, S., Ganjali, M. R., Norouzi, P., Hosseini, M., & Abdollahi, M. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.07.047 · Cited by 174
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
The Oral Glucose Tolerance Test: 100 Years Later
Jagannathan, R., Neves, J. S., Dorcely, B., Chung, S. T., Tamura, K., Rhee, M., & Bergman, M. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s246062 · Cited by 152
Sex differences underlying pancreatic islet biology and its dysfunction
Gannon, M., Kulkarni, R. N., Tse, H. M., & Mauvais-Jarvis, F. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.017 · Cited by 133
“Further, Davis et al. performed glucose clamps on healthy human subjects and reported that females showed lower glucagon response to equivalent fixed hypoglycemia and hyperinsulinemia compared to age-and-BMI-matched males [73].”
MethodResultInfluentialGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“…prediabetes or type 2 diabetes had a 25% lower GLP-1 response to an oral glucose-tolerance test (OGTT) than individuals with normal glucose tolerance, and both men and women with prediabetes or type 2 diabetes had 16–21% lower 120-min GLP-1 plasma concentrations, independent of age and obesity 76 .”
Self-citationThe Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationWewer Albrechtsen, N. J., Færch, K., Jensen, T. M., Witte, D. R., Pedersen, J., Mahendran, Y., Jonsson, A. E., Galsgaard, K. D., Winther-Sørensen, M., Torekov, S. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4535-5 · Cited by 119
Self-citationGLP1R Attenuates Sympathetic Response to High Glucose via Carotid Body Inhibition
Pauza, A. G., Thakkar, P., Tasic, T., Felippe, I., Bishop, P., Greenwood, M. P., Rysevaite-Kyguoliene, K., Ast, J., Broichhagen, J., Hodson, D. J., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319874 · Cited by 106
Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36
Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101
Self-citationLiraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study
Ellingsgaard, H., Seelig, E., Timper, K., Coslovsky, M., Soederlund, L., Lyngbæk, M. P. P., Albrechtsen, N. J. W., Schmidt‐Trucksäss, A., Hanssen, H., Frey, W. O., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-05045-y · Cited by 105
Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
The Emerging Role of Polyphenols in the Management of Type 2 Diabetes
Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88
“In addition to ingested nutrients, GLP-1 secretion could also be influenced by other factors such as sex [55], obesity, insulin resistance, β-cell function, and diabetes state [57].”
BackgroundManell, H., Staaf, J., Manukyan, L., Kristinsson, H., Cen, J., Stenlid, R., Ciba, I., Forslund, A. H., & Bergsten, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3885 · Cited by 99
Dollerup, O. L., Trammell, S. A. J., Hartmann, B., Holst, J. J., Christensen, B., Møller, N., Gillum, M. P., Treebak, J. T., & Jessen, N. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01081 · Cited by 77
Hygum, K., Starup‐Linde, J., & Langdahl, B. L. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.05.001 · Cited by 94
Shadid, S., Abosi-Appeadu, K., De Maertelaere, A.-S., Defreyne, J., Veldeman, L., Holst, J. J., Lapauw, B., Vilsbøll, T., & T’Sjoen, G. (2020) · Diabetes Care · doi:10.2337/dc19-1061 · Cited by 82
“1,400 subjects with a large range of BMIand insulin sensitivity suggested that post-OGTT GLP-1 response was higher in women than in men, but this difference was lostwith increasing insulin resistance (39).”
BackgroundGlucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 78
Hygum, K., Harsløf, T., Jørgensen, N. R., Rungby, J., Pedersen, S. B., & Langdahl, B. L. (2020) · Bone · doi:10.1016/j.bone.2019.115197 · Cited by 75
What is GLP-1 really doing in obesity?
Hira, T., Pinyo, J., & Hara, H. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.09.003 · Cited by 74
17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells
Handgraaf, S., Dusaulcy, R., Visentin, F., Philippe, J., & Gosmain, Y. (2018) · JCI Insight · doi:10.1172/jci.insight.98569 · Cited by 73
Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery
Svane, M. S., Bojsen-Møller, K. N., Nielsen, S., Jørgensen, N. B., Dirksen, C., Bendtsen, F., Kristiansen, V. B., Hartmann, B., Holst, J. J., & Madsbad, S. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2015 · Cited by 72
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
Wewer Albrechtsen, N. J., Hornburg, D., Albrechtsen, R., Svendsen, B., Toräng, S., Jepsen, S. L., Kuhre, R. E., Hansen, M., Janus, C., Floyd, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.034 · Cited by 69
“…that secretion of GLP-1 is blunted in some subjectswith type 2 diabetes, and recent large-scale human studies suggest that the decreased GLP-1 responses may contribute to the development of type 2 diabetes (Calanna et al., 2013; Færch et al., 2015; Meier and Nauck, 2010; Nauck et al., 2011).”
BackgroundAhmed, M., Kumari, N., Mirgani, Z., Saeed, A., Ramadan, A., Ahmed, M. H., & Almobarak, A. O. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00965-2 · Cited by 88
Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases
Zhou, M., Johnston, L. J., Wu, C., & Ma, X. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1986466 · Cited by 70
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“In the NGT group, the time taken to reach maximum peak concentrations was between 20 [42,43] and 30 min [39,44 – 47], whereas in the IGT group, the time was between 30 [39,44,46,47] and 45 min [48], in TD2M group, the time was between 30 and 90 min (most studies observed a peak at 30 min) [39,44 –…”
BackgroundResultInfluentialSelf-citationMøller, C. L., Vistisen, D., Færch, K., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Jørgensen, M. E., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3133 · Cited by 62
Stinson, S. E., Jonsson, A. E., Lund, M. A. V., Frithioff‐Bøjsøe, C., Holm, L. A., Pedersen, O. B., Ängquist, L. H., Sørensen, T. I. A., Holst, J. J., Christiansen, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab098 · Cited by 66
Farhadipour, M., & Depoortere, I. (2021) · Nutrients · doi:10.3390/nu13061839 · Cited by 75
“A study in a large cohort of obese patients showed a ~20% reduction in GLP-1 response to oral glucose compared with normal weight individuals [48].”
BackgroundSandberg, J. C., Björck, I., & Nilsson, A. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151985 · Cited by 73
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“GLP-1 secretion seems to be impaired in obese subjects, which informs at least the partial role of GLP-1 in the pathophysiology of obesity [94–96].”
Glucagon‐like peptide‐1 receptor is expressed in human and rodent testis
Caltabiano, R., Condorelli, D. F., Panza, S., Boitani, C., Musso, N., Ježek, D., Memeo, L., Colarossi, L., Rago, V., Mularoni, V., et al. (2020) · Andrology · doi:10.1111/andr.12871 · Cited by 63
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Merabet, N., Lucassen, P. J., Crielaard, L., Stronks, K., Quax, R., Sloot, P. M. A., la Fleur, S. E., & Nicolaou, M. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100972 · Cited by 87
“This sex difference disappeared in (pre-)diabetic individuals (Færch et al., 2015).”
Obesity and male fertility disorders
Cannarella, R., Crafa, A., Curto, R., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101273 · Cited by 75
Osinski, C., Gléau, L. L., Poitou, C., de Toro‐Martín, J., Genser, L., Fradet, M., Soula, H. A., Leturque, A., Blugeon, C., Jourdren, L., et al. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-00694-1 · Cited by 57
Squire, P., Naude, J., Zentner, A., Bittman, J., & Khan, N. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089477 · Cited by 47
Hira, T., 須藤僚也, Kishimoto, Y., Kanahori, S., & Hara, H. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1381-7 · Cited by 54
Elkind-Hirsch, K. E., Shaler, D., & Harris, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107548 · Cited by 53
Strack, C., Behrens, G., Sag, S. J. M., Mohr, M., Zeller, J., Lahmann, C., Hubauer, U., Loew, T. H., Maier, L. S., Fischer, M., et al. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00416-4 · Cited by 67
Skeletal Fragility in Type 2 Diabetes Mellitus
Starup‐Linde, J., Hygum, K., & Langdahl, B. L. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.3.339 · Cited by 48
“In patients with T2D, the effect of feeding on bone resorption is reduced compared with non-diabetes patients [61], possibly by an impaired GLP-1-response [62].”
BackgroundSartorius, T., Weidner, A., Dharsono, T., Boulier, A., Wilhelm, M. G., & Schön, C. (2019) · Nutrients · doi:10.3390/nu11071700 · Cited by 52
Jácome-Sosa, M., Parks, E. J., Bruno, R. S., Tasali, E., Lewis, G. F., Schneeman, B. O., & Rains, T. M. (2016) · Advances in Nutrition · doi:10.3945/an.115.010397 · Cited by 51
Incretin secretion in humans is under the influence of cannabinoid receptors
Chia, C. W., Carlson, O. D., Liu, D. D., González-Mariscal, I., Santa-Cruz Calvo, S., & Egan, J. M. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00080.2017 · Cited by 43
Increase in clinically recorded type 2 diabetes after colectomy
Jensen, A. B., Sørensen, T. I. A., Pedersen, O. B., Jess, T., Brunak, S., & Allin, K. H. (2018) · eLife · doi:10.7554/elife.37420 · Cited by 45
“Recent studies suggest that modifications in GLP-1 release are directly involved in both development of diabetes (Færch et al., 2015) and diabetes remission after gastric bypass (Holst and Madsbad, 2016).”
BackgroundManell, E., Hedenqvist, P., Svensson, A. C., & Jensen‐Waern, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148896 · Cited by 51
King, K., Lin, N.-P., Cheng, R. Y.-H., Chen, G.-H., & Chein, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672097 · Cited by 44
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
Zhao, M., Ren, K., Xiong, X., Cheng, M., Zhang, Z., Huang, Z., Han, X., Yang, X., Alejandro, E. U., & Ruan, H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108013 · Cited by 44
“Studies suggest that defects in EEC function and gut hormone secretion are associated with human obesity and diabetes (ToftNielsen et al., 2001; Vilsbøll et al., 2001; Faerch et al., 2015).”
BackgroundEnteroendocrine cell differentiation and function in the intestine
Sanchez, J. G., Enriquez, J. R., & Wells, J. M. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000709 · Cited by 41
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 47
Gut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“In T2D individuals, including those with prediabetes, meal-stimulated GLP-1 secretion is generally impaired (Faerch et al., 2015).”
BackgroundJensen, C. Z., Bojsen-Møller, K. N., Svane, M. S., Holst, L. M., Hermansen, K., Hartmann, B., Albrechtsen, N. J. W., Kuhre, R. E., Kristiansen, V. B., Rehfeld, J. F., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00265.2019 · Cited by 44
Otten, J., Ryberg, M., Mellberg, C., Andersson, T., Chorell, E., Lindahl, B., Larsson, C., Holst, J. J., & Olsson, T. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0082 · Cited by 36
Identification of dipeptidyl peptidase IV inhibitory peptides from rapeseed proteins
You, H., Zhang, Y., Wu, T., Li, J., Wang, L., Yu, Z., Liu, J., Liu, X., & Ding, L. (2022) · LWT · doi:10.1016/j.lwt.2022.113255 · Cited by 36
New insight of obesity-associated NAFLD: Dysregulated “crosstalk” between multi-organ and the liver?
Wang, Y., Wu, L.-L., Qi, X.-Y., Wang, Y.-Y., Liao, Z., Liu, J., & Xiao, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.013 · Cited by 40
Two weeks of exercise training intensity on appetite regulation in obese adults with prediabetes
Heiston, E. M., Eichner, N. Z. M., Gilbertson, N. M., Gaitán, J. M., Kranz, S., WELTMAN, A. L., & Malin, S. K. (2019) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00655.2018 · Cited by 34
Holliday, A., & Blannin, A. (2017) · Nutrients · doi:10.3390/nu9040362 · Cited by 34
Hytting-Andreasen, R., Balk-Møller, E., Hartmann, B., Pedersen, J., Windeløv, J. A., Holst, J. J., & Kissow, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198046 · Cited by 36
Guardado‐Mendoza, R., Salazar-López, S. S., Alvarez-Canales, M. F. D. L. L., Farfán-Vázquez, D., Martínez-López, Y. E., Jiménez-Ceja, L. M., Suárez-Pérez, E. L., Angulo-Romero, F., Evia-Viscarra, M. L., de Oca-Loyola, M. L. M., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154054 · Cited by 37
Jujić, A., Nilsson, P. M., Atabaki-Pasdar, N., Dieden, A., Tuomi, T., Franks, P. W., Holst, J. J., Torekov, S. S., Ravassa, S., Díez, J., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1318 · Cited by 33
Almario, R. U., Buchan, W., Rocke, D. M., & Karakas, S. E. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000420 · Cited by 37
Cannarella, R., Curto, R., Condorelli, R. A., Lundy, S. D., Vignera, S. L., & Calogero, A. E. (2024) · Nature Communications · doi:10.1038/s41467-024-49765-1 · Cited by 37
“Similarly, GLP-1 secretion is impaired in patients with obesity or T2DM 126,127 .”
BackgroundXie, C., Huang, W., Watson, L. E., Soenen, S., Young, R. L., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab828 · Cited by 33
Larsen, J. R., Svensson, C. K., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. S. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2018) · CNS Spectrums · doi:10.1017/s1092852918001311 · Cited by 35
“to nutrients compared to NGT individuals has been reported.(52,53) Therefore, these findings suggest that a reduced GLP-1 secretion is present before overt T2D, and therefore may contribute not only to increased appetite but also to the development of T2D.”
BackgroundGlucagon-like peptide-1 receptor agonist stimulates mitochondrial bioenergetics in human adipocytes
Góralska, J., Śliwa, A., Gruca, A., Raźny, U., Chojnacka, M., Polus, A., Solnica, B., & Malczewska-Malec, M. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2017_1634 · Cited by 34
“The GLP-1 plasma level is decreased and consecutively the insulinotropic effect of this incretin is diminished in type 2 diabetes, in obesity or after bariatric surgery (Færch et al., 2015).”
BackgroundRameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“23 The GIP response to stimulation is also found to increase in obesity, which potentially suggest an attenuation of the incretin effect of GIP.”
Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity
Hira, T., Trakooncharoenvit, A., Taguchi, H., & Hara, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126623 · Cited by 32
Dieck, H. T., Schön, C., Wagner, T., Pankoke, H., Fluegel, M., & Speckmann, B. (2021) · Nutrients · doi:10.3390/nu14010143 · Cited by 38
“Recently, Wu et al. found out that several butyrate producers and functional potential for butyrate production were decreased both in prediabetes and in type 2 diabetes (T2D) [35], confirming earlier findings by Zhang et al. on reduced butyrate-production capacity during the progression of glucose intolerance [36].”
BackgroundLee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 33
Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
“Interestingly, the GLP-1 response following a glucose load is reduced in individuals with obesity 29 .”
Schwartz, A. B., Kapur, A., Huang, Z., Anangi, R., Spear, J. M., Stagg, S. M., Fardone, E., Dekan, Z., Rosenberg, J. T., Grant, S. C., et al. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15200 · Cited by 30
“Previous studies have shown that QDs are cleared within hours or days, depending on route of delivery (Fischer et al., 2006; Medintz et al., 2008).”
BackgroundVahdatpour, T., Nokhodchi, A., Zakeri‐Milani, P., Abbasi, M. M., Ahmadiasl, N., & Valizadeh, H. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13018 · Cited by 25
Shamshoum, H., Medak, K. D., & Wright, D. C. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113049 · Cited by 32
Xie, C., Huang, W., Sun, Y., Xiang, C., Trahair, L. G., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad176 · Cited by 27
Metadata
- Authors
- Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., Holst, J. J., & Jørgensen, M. E.
- Affiliations
- Steno Diabetes Center, Gentofte, Denmark
- University of Copenhagen (DK)
- Danish Diabetes Academy (DK)
- Section for General Practice, Department of Public Health, Aarhus, Denmark
- Corresponding author
- Færch, Kristine
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-02-12
- Volume
- 64
- Issue
- 7
- Pages
- 2513-2525
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2081594150
- Cited by
- 321
- References
- 54
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 28 · 2022: 27 · 2021: 34 · 2020: 28 · 2019: 41 · 2018: 26 · 2017: 20 · 2016: 22 · 2015: 11
- FWCI
- 22.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Foundation
- Danish Centre for Evaluation and Health Technology Assessment
- Diabetes Fund of the National Board of Health
- Danish Medical Research Council
- Aarhus University Research Foundation
- European Foundation for the Study of Diabetes/Pfizer for Research into Cardiovascular Disease Risk Reduction in Patients with Diabetes (74550801)
- National Health Services in the counties of Copenhagen, Aarhus, Ringkøbing, Ribe, and Southern Jutland in Denmark
- Danish Council for Strategic Research
- Danish Research Foundation for General Practice
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, glucose-stimulated insulin secretion, prediabetes, type 2 diabetes, obesity, sex differences, oral glucose tolerance test, insulin sensitivity, beta-cell function
- MeSH terms
- Age Factors, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Male, Middle Aged, Obesity, Prediabetic State, Sex Characteristics, Body Mass Index, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.